Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
(s_account); var hd1 document.getElementById('headline'); s.tl(this'o'getLinkName('Company Sanpshot')); VNUS ) is a worldwide leader in medical devices forthe minimally invasive treatment of venous reflux disease a progressivecondition that causes the varicose veins afflicting 25 million Americans.The pioneering company in the field VNUS now offers the ClosureFASTsystem which consi
Date:11/14/2007
(s_account); var hd1 = document.getElementById('headline'); s.tl(this,'o',getLinkName('Company Sanpshot'));" >VNUS) is a worldwide leader in medical devices for
the minimally invasive treatment of venous reflux disease, a progressive
condition that causes the varicose veins afflicting 25 million Americans.
The pioneering company in the field, VNUS now offers the ClosureFAST
system, which consists of a proprietary radiofrequency (RF) generator and
proprietary disposable endovenous catheters and devices to close diseased
veins through the application of temperature-controlled RF energy. VNUS
devices have been used in more than 250,000 procedures worldwide. For more
information, please visit
http://www.vnus.com.
'/>"/>SOURCE VNUS Medical Technologies, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 Related medicine technology :1.
Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-882.
Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX3.
Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting4.
Influenza is Leading Cause of Vaccine-Preventable Deaths for Kids; Despite CDC Recommendations, Moms Still Dont Vaccinate5.
Mayo Clinic Physicians Report Findings from Research on Sleep Disorders6.
Bayer Issues Additional Guidance to Physicians on Trasylol(R)7.
Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA8.
Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate9.
Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference10.
Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)11.
Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference